MobbleOpen in Mobble ⇢
Health · Drug development · published 2026-10-08 · via BiopharmaWatch

CRISPR Therapeutics to Share Phase 1b Data for CTX310 at AHA 2026

Image via BiopharmaWatch
Image via BiopharmaWatch

CRISPR Therapeutics will present late-breaking Phase 1b results for CTX310 at the American Heart Association Scientific Sessions 2026. CTX310 is an in vivo CRISPR/Cas9 gene editing therapy targeting ANGPTL3 in patients with severe hypertriglyceridemia. The oral presentation is scheduled for November 9, 2026.

Expanded Detail

CRISPR Therapeutics said Phase 1b results for CTX310 will be featured as late-breaking oral science at the American Heart Association Scientific Sessions 2026, held Nov. 6–9. The session is scheduled for Nov. 9 at 8:00 a.m. CST. CTX310 is an investigational in vivo CRISPR/Cas9 therapy designed to target ANGPTL3 in severe hypertriglyceridemia.

Data remain embargoed until presentation, after which slides will be posted on the company’s website. CRISPR Therapeutics uses a lipid nanoparticle liver-editing platform and also lists cardiovascular candidates CTX340 for refractory hypertension and CTX321 for elevated lipoprotein(a), plus CTX460 for alpha-1 antitrypsin deficiency.

Context

If the Phase 1b results are encouraging, CTX310 could affect people with severe hypertriglyceridemia and related cardiometabolic conditions by expanding future treatment possibilities. Clinicians, researchers, and drug developers may watch the data for signals on in vivo liver editing. Any broad societal impact would depend on safety, durability, affordability, and access, so benefits remain uncertain at this early stage.

Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Read the full article at BiopharmaWatch →
Related stories
Vir Biotechnology to Unveil Latest Hepatitis Delta Trial Data · Drug development
Equillium Gains Australian Approval to Launch Phase 1 Study of Autoimmune Therapy · Drug development
Nurix Advances Leukemia Treatment With First Patient in Combination Therapy Study · Cancer research
Ascendis Pharma Presents Five-Year Clinical Data on Rare Disease Treatments · Drug development
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026.” Browse more stories.